Via Pharmaceuticals Inc · OTC:VIAP
Via Pharmaceuticals — Corautus Genetics — Shareholder Meeting (May 2004)
14 slides from Via Pharmaceuticals's shareholder meeting presentation, May 7, 2004
Slide 1: Annual Meeting of Stockholders, May 7, 2004
Annual May Richard President 1 7, 2004 Stockholders E.and Otto Chief Executive Meeting Officer
Slide 2: Forward-Looking Statements
Forward-Looking This factors, operating the our Corautus (File 2 alliance proposed presentation No.risks 001-15833) Genetics performance, with and products, Boston uncertainties may Statements Inc.’s filed contain approval events Scientific, Securities March forward-looking or that of developments 3
Slide 3: Company History
Company Vascular GenStar Corautus The 3 Merged Therapeutics Genetics Genetics History CompanyInc. Inc.Inc. – February 5, 2003
Slide 4: Corautus Genetics at a Glance
Corautus The Initial CAD Clinical Strategic 4 Cash:Target: Science: Market Market: Focus: Status: Genetics: Alliances: Vascular $14.5M Cap: Genomic Refractory Estimated Phase $75M At asEndothelial 3/31/04Boston I/IIa aTherapeutics of Glance $1 Myocardial Completed; billion Scientific 5/4/04 Growth i
Slide 5: Corautus' VEGF-2 Technology
•Corautus’ – 5 What How A When naturally does isinjected VEGF-2 VEGF-2 VEGF-2 occurring in Technology towork ischemic growth factor musclethat tissue, stimulates the VEGF-2 the migration gene encodes and growth the VEGF-2 of endothelial protein cells, and isessential believedcomponents to stimulate
Slide 6: Tribute to Jeffrey M. Isner, M.D.
Jeffery ‘No and Cardiology 6 without discussion M. Isner, Rounds question onM.D. therapeutic Harvard the & pioneer Vascular Medical angiogenesis inGenetics this School area.’ would Inc. January be 2002 appropriate without honoring the person who was clearly the leader in the field. Dr. Jeffery M. Is
Slide 7: The Vision
The Vision Pharmacologic Conventional Regenerative vs. Treats Underlying Biologic 7 Symptom Cause (Genetic) revascularization –condition Biologicaltered unaltered Revascularization may offer superior outcomes in the treatment of refractory angina due to remodeling of ischemic cardiac muscle
Slide 8: Phase IIb Clinical Trial Design
Phase National N Class Boston Efficacy 15 Primary Secondary 8 =clinical 404, III Ilb Scientific Endpoint data and multi-center, four Clinical sites Endpoint IV measured cohorts in angina StilettoTM Trial –the Increase –(0, United double-blind, SPECT Design “no at20?g, 3 op” months, in Catheter State
Slide 9: FDA Review Process
FDA can Responsible Reports Dialogue Trial Center Reviews Delivers 9 Review for all comments submission not ongoing—additional Biologics Devices CBER for commence Process complete and and toEvaluation and focusing of CBER CDRH Radiological Combination until refers review the on comments guidance dev
Slide 10: Recent Corporate Accomplishments
Recent OBJECTIVE: Corporate Settle 10 Moved Accomplishments Negotiate Received Prepare Negotiated Commence and Commenced Extend Raise Restructuring Major RESULTS: settlement commercialization Capital Key headquarters for$12.5 Major clinical Phase Manufacturing License manufacturing 10.7M Million Str
Slide 11: A Strengthened Balance Sheet
Building March in Cash Property Accounts Lease Other Stockholders’ Total 11 thousands and assets current liabilities 734 current long settlement 31,and Shareholder cash payable 2004 term $liabilities assets equipment, assets liabilities 15,880 Equity equivalents 7,321 and liabilities obligation &14,
Slide 12: Corautus Stock Price Performance
Stock Corautus For $1.40 12 theCorautus Price 12compared month Performance Stock period to Price NASDAQ ended Graph $6.00 MayBiotech 4, 2004 Index (NBI) and AMEX Biotech Index (BTK)
Slide 13: Management Goals 2004
Management Commence Initiate Efficiently Secure Consider Achieve 13 additional phase another filing deploy and Goals III-commercial new Manage year funding capital for protocol of2004 significant Phase by forcontrolling to product 2005 IIb existing CAD and valuation manufacturing beyond Investigatio
Slide 14: Conclusion
“Later-stage” Conclusion Support $1 Major Strong Experienced 14 billion collaboration intellectual ofestimated keyand therapeutic opinion focused property US agreement leaders annual management serving position in with market an cardiology Boston unmet Strengthened team opportunity medical Scientifi